Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Core Insights - Abivax announced significant improvements in patient-reported outcomes (PRO) from its Phase 3 ABTECT trials for obefazimod, indicating its potential to enhance the quality of life for patients with moderate-to-severely active ulcerative colitis [2][5] Summary by Categories Clinical Trial Results - The Phase 3 ABTECT trials demonstrated that 37% of patients on 50mg obefazimod reported no bowel urgency at week 8, compared to 18.1% in the placebo group (p<0.0001) [6] - 47.6% of patients on 50mg obefazimod reported no nocturnal bowel movements at week 8, compared to 24.7% in the placebo group (p<0.0001) [6] - Fatigue remission was reported by 17.1% of patients on 50mg obefazimod at week 8, compared to 7.7% in the placebo group (p=0.0001) [6] Patient-Reported Outcomes - PRO instruments evaluated included bowel urgency, nocturnal bowel movements, fatigue, overall quality of life, and workplace productivity [7] - Consistent improvements across all PRO instruments were observed, underscoring the meaningful benefits of obefazimod for patients' daily experiences [3][5] Future Developments - Abivax plans to present detailed PRO data at an upcoming medical conference and anticipates sharing results from a 44-week maintenance trial in the second quarter of 2026 [4][5] - The company is focused on developing effective and tolerable long-term therapies for ulcerative colitis [5][8]